{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7","value":"1.0"},{"groupId":"OG001","spread":"0.5","value":"0.9"},{"groupId":"OG002","spread":"0.6","value":"1.0"}]}],"title":"PB CD34+ count (Baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.0","value":"5.7"},{"groupId":"OG001","spread":"2.1","value":"4.0"},{"groupId":"OG002","spread":"2.9","value":"4.6"}]}],"title":"PB CD34+ count (3 hours after infusion)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.9","value":"6.3"},{"groupId":"OG001","spread":"2.7","value":"4.3"},{"groupId":"OG002","spread":"3.3","value":"5.1"}]}],"title":"PB CD34+ count (6 hours after infusion)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.4","value":"7.8"},{"groupId":"OG001","spread":"3.7","value":"5.2"},{"groupId":"OG002","spread":"4.1","value":"6.5"}]}],"title":"PB CD34+ count (Maximum increase)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"7 patients with MM were enrolled.","id":"OG000","title":"Multiple Myeloma (MM)"},{"description":"10 patients and 2 patients with NHL and HD were enrolled, respectively.","id":"OG001","title":"Non-Hodgkin Lymphoma (NHL) + Hodgkin Disease (HD)"},{"description":"All patents = MM + NHL + HD","id":"OG002","title":"All Patients"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline, 3 hours and 6 hours after infusion","title":"Circulating CD34+ Cell Counts in Peripheral Blood.","type":"SECONDARY","unitOfMeasure":"cells/μL"}